BriaCell Therapeutics Corp. has announced that the Data Safety Monitoring Board (DSMB) has recommended the continuation of its Phase 3 clinical trial evaluating Bria-IMT™ in combination with an immune checkpoint inhibitor for metastatic breast cancer. The DSMB, an independent group of experts, found no safety concerns after reviewing data from patients enrolled in the randomized study (NCT06072612).
The positive recommendation allows BriaCell to continue its pivotal Phase 3 study without any modifications. The trial is currently under Fast Track Designation with the FDA, potentially expediting the drug's development and review process.
Management Commentary
"We are pleased with the DSMB’s recommendation for the continuation of BriaCell’s Phase 3 study without any protocol modification as a significant milestone towards clinical advancement of our novel immunotherapy as a safe and effective treatment option for metastatic breast cancer patients," stated Dr. William V. Williams, BriaCell’s President & CEO.
Giuseppe Del Priore, MD, MPH, BriaCell’s Chief Medical Officer, added, "We strongly believe in the potential of our novel immunotherapy to transform cancer care for metastatic breast cancer patients, and the positive DSMB review reinforces our confidence in the potential use of the combination regimen in metastatic breast cancer patients."
About the Phase 3 Trial
The Phase 3 trial is designed to evaluate the safety and efficacy of Bria-IMT™ in combination with an immune checkpoint inhibitor in patients with metastatic breast cancer. The study aims to enroll patients who have progressed on prior therapies, addressing a significant unmet need in this patient population. The combination therapy seeks to harness the body's immune system to target and destroy cancer cells.
Bria-IMT™: A Novel Immunotherapy
Bria-IMT™ is BriaCell's lead investigational immunotherapy. It is designed to activate the immune system to recognize and eliminate cancer cells. The therapy is being developed as a potential treatment option for patients with advanced breast cancer. The combination with immune checkpoint inhibitors is intended to enhance the anti-tumor immune response.
